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Abstract Expression profiling with DNA microarrays has
been used to examine the transcriptome of a wide spectrum
of vertebrate cells and tissues. The sensitivity and accuracy
of the data generated is dependent on the quality and
composition of the input RNA. In this report, we examine
the quality and array performance of over 200 total RNA
samples extracted from ocular tissues and cells that have
been processed in a microarray core laboratory over a 7-
year period. Total RNA integrity and cRNA target size
distribution were assessed using the 2100 Bioanalyzer. We
present Affymetrix GeneChip array performance metrics
for different ocular samples processed according to a
standard microarray assay workflow including several
quality control checkpoints. Our review of ocular sample
performance in the microarray assay demonstrates the value
of considering tissue-specific characteristics in evaluating
array data. Specifically, we show that Bioanalyzer electro-
pherograms reveal highly abundant mRNAs in lacrimal
gland targets that are correlated with variation in array
assay performance. Our results provide useful benchmarks
for other gene expression studies of ocular systems.
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Introduction
Expression profiling with DNA microarrays has been
widely applied over the last decade to measure differences
in gene expression patterns in a large variety of research
samples and clinical specimens. High-density microarrays
are able to survey the genome-wide transcriptome of a
particular organism and present a ‘snapshot’ of gene
expression in the cell or tissue sample at the time of RNA
isolation. These profiles are generated from both homoge-
nous and heterogeneous collections of cells and provide
measures of messenger RNA (mRNA) levels from low to
high abundance. The quality of the RNA samples used in
these studies is crucial in generating accurate and informa-
tive results. Previous reports have described the value of
determining RNA purity and integrity prior to selecting
samples for microarray hybridization [1–3]. Currently, these
sample attributes are commonly determined by UV spec-
trophotometry and RNA sizing with capillary electropho-
resis on the 2100 Bioanalyzer, a microfluidics platform for
electrophoretic separation of biomolecules [4]. In addition
to the impact of RNA degradation on microarray analysis,
we and others have observed that highly abundant
hemoglobin RNA transcripts present in whole blood RNA
samples can reduce overall mRNA detection sensitivity and
increase sample-to-sample variation in the microarray assay
[5–8]. These abundant RNA transcripts are not detectable in
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DOI 10.1007/s12177-009-9046-2Bioanalyzer traces of total RNA, but can often be seen
in the electrophorpherogram patterns of the amplified
and labeled targets prepared for microarray hybridization
[6, 8–10].
In our microarray core laboratory, we have processed
over 6,000 RNA samples from human, monkey, mouse, rat,
and other vertebrates. Each total RNA sample is assessed
for integrity using the 2100 Bioanalyzer. RNA quality is
determined by visual inspection of the electropherogram
and the RNA integrity number (RIN) [11, 12] generated by
the Bioanalyzer software program. Samples which pass
core laboratory defined thresholds are converted to micro-
array hybridization targets and subjected to another round
of quality assessment by Bioanalyzer analysis prior to
application to the DNA microarray. The experimental
workflow in the core laboratory is diagramed in Fig. 1.
The points at which sample and data quality are inspected is
illustrated to the right of the flow diagram.
Approximately 200 of the samples analyzed in the core
laboratory have been extracted from ocular tissues and cell
lines. In this report, we describe the use of Bioanalyzer-
generated electropherograms to assess RNA quality and
predict microarray assay performance of ocular tissue
samples, and we demonstrate how electropherograms of
labeled cRNA targets can provide insight on characteristic
RNA patterns associated with different tissue types. We
show that while ocular RNA samples that pass total RNA
quality assessment thresholds generally produce high-
quality microarray data, RNA from lacrimal gland and
primary acinar cell cultures expresses abundant levels of a
few mRNAs that may impact sensitivity and contribute to
sample-to-sample variation in the microarray profiling
assay.
Materials and methods
Samples
The samples analyzed in this study were submitted to the
Affymetrix Microarray Core laboratory of the OHSU Gene
Microarray Shared Resource over the period of 2002 to
2009. Tissues or cell cultures were harvested and RNA was
isolated in the client laboratory. RNA samples were isolated
using one of the following commercial kits: RNA aqueous
(Ambion, Inc., Austin, TX, USA), Trizol Reagent (Invi-
trogen, Inc., Carlsbad, CA, USA), and RNeasy Total RNA
(Qiagen, Inc., Valencia, CA, USA). Total RNA from ocular
tissues and cell lines examined in this study were provided
by Dr. Mitzuyoshi Azuma of the Senju Laboratory for
Ocular Sciences at OHSU and Dr. Justine Smith of the
Casey Eye Institute at OHSU.
Bioanalyzer analysis
Total RNA quality was assessed by determining UV 260/
280 absorbance ratios and examining RNA size distribution
on RNA Nano LabChips (Agilent Technologies, Santa
Clara, CA, USA) processed on the Agilent 2100 Bioana-
lyzer using the total RNA electrophoresis program. For
samples analyzed after 2003, a RIN was generated for each
Bioanalyzer trace using 2100 Expert Software (Agilent
Technologies). The maximum RIN score is 10. Labeled
cRNA targets generated from the total RNA samples were
examined using the mRNA program on the Bioanalyzer.
There is no numerical scoring algorithm for this program.
Target labeling
All RNA samples were processed for array hybridization
using the GeneChip one-cycle target labeling kit (Affyme-
trix, Inc, Santa Clara, CA, USA) for amplification and
labeling of total RNA. Target synthesis was performed
following the Affymetrix GeneChip Expression Analysis
Technical Manual, rev. 5 (http://www.affymetrix.com/
support/technical/manual/expression_manual.affx)w i t h
minor modification. Using 2–4 µg of total RNA as input,
mRNA was converted to double-stranded cDNA and
Fig. 1 Experimental workflow in the microarray core laboratory.
Total RNA samples are provided to the microarray core laboratory
after consultation with clients on experimental design, array selection,
and sample preparation. As illustrated to the right of the flow chart,
sample quality is checked prior to target synthesis, targets are assessed
prior to microarray hybridization, and array data is examined for
individual array performance and data distribution patterns across
samples within a project. Sample, target, and array performance data
are collected in a laboratory information management system for
centralized information tracking and to facilitate comparisons among
projects and sample types
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and ethanol precipitation. In a second step, amplified and
biotinylated cRNA (the target) was produced by in vitro
transcription. Unincorporated nucleotides were removed
using the RNeasy Mini kit (Qiagen Inc., Valencia, CA,
USA) followed by ethanol precipitation of the labeled
target. After resuspension in RNase-free water, each target
was quantified by UV260 absorbance.
Microarray hybridization and processing
Labeled targets were chemically fragmented as per Affy-
metrix’ recommendations and combined with Affymetrix
biotinylated hybridization controls (oligomer B2 and
cRNAs for BioB, BioC, BioD, and CreX) in hybridization
buffer. Hybridizations were performed for 16 h at 45°C
after addition of 10 µg of target to the GeneChip array
(Affymetrix) selected for each analysis. In general, species-
matched oligonucleotide arrays were used for each target.
However, microarray assays of monkey tissues before 2004
were performed on human arrays. Post-hybridization array
processing of all arrays was performed according to
manufacturer’s recommendations for the array type.
Microarray analysis and performance assessment
The array image scan was processed with Affymetrix
Microarray Suite, version 5.0 (MAS 5.0) software. All
GeneChip expression arrays included in this study contain
control probe sets for both spiked and endogenous RNA
transcripts (e.g., BioB, BioC, BioD, CreX, and species-
specific actin and GAPDH). Following single-array analysis
of the array signal intensity pattern with MAS 5.0, six values
were examined to assess overall assay performance: back-
ground,noise,average signal,%present,ratioofsignalvalues
for probe sets representing the 5′ and 3′ ends of actin and
GAPDH transcripts, and total signal for BioB, BioC, BioD,
andCreXprobe sets. Genetranscriptlevelsare determinedfor
each sample from the MAS generated .CHP files. Relative
performance of groups of related samples is examined using
visualization graphs of gene level data distributions, such as
scatter and box plots, with Expression Console (Affymetrix)
and Statistica (StatSoft, Tulsa, OK, USA).
Results
Total RNA quality assessment in the microarray core
facility
The core lab received total RNA from ocular tissues,
primary cultures, and cell lines collected or derived from
three mammalian species: human, monkey, and rat. For
each sample, RNA purity was assessed by OD 260/280
values and RNA integrity by size distribution analysis on
the 2100 Bioanalyzer. All sample electropherograms are
assessed for total RNA quality by visual inspection and,
after 2003, by RIN score. Minimum requirements for a pass
in the core laboratory are an RNA integrity value greater
than 7.8 and a 260/280 ratio greater than 1.7. Of the 206
ocular RNA samples submitted, all had acceptable OD 260/
280 values, between 1.8 and 2.2. RIN scores varied from no
call to 10; however, the vast majority of samples received
RIN scores between 8.5 and 10. Altogether, eight different
ocular tissues, primary cell cultures, or cell lines were
assessed. The mean RIN for each ocular cell or tissue type
for which the core laboratory processed more than two
samples and for which a RIN score is available is shown in
Table 1; highly degraded samples with RIN scores less than
7 were excluded. Fewer than ten samples showed extensive
RNA degradation (data not shown).
Target cRNA pattern analysis
In total, 181 RNA samples were converted to amplified and
biotin-labeled cRNA targets for microarray hybridization.
An aliquot of each cRNA target was analyzed on the 2100
Bioanalyzer. A typical size distribution profile for mamma-
lian targets that perform well in the GeneChip microarray
assay is shown in Fig. 2a. In general, each ocular tissue or
cell line target demonstrated a size distribution profile
consistent with high-quality total RNA samples prepared
from other mammalian tissues profiled in the core labora-
tory (Fig. 2b, c, and d). However, targets produced from
lacrimal gland RNA or acinar cells prepared from lacrimal
glands showed an additional sharp peak or several smaller
peaks in the profile (Fig. 2e and f). The height of this peak
varied among lacrimal gland samples.
Tissue/cell No. of samples Average RIN
Conjunctiva primary culture 3 9.9
Lacrimal gland acinar cells 19 9.4
Retinal endothelial cells 20 9.6
Choroid endothelial cells 18 9.6
Retinal pigment epithelial cell line 12 10
Cornea epithelium cell line 16 10
Table 1 Bioanalyzer RIN
scores for total RNA samples
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quality control step in excluding samples that will perform
poorly in the microarray assay, we compared targets and
microarray performance from a retinal endothelial sample
with a subthreshold RIN score (4.3) to other high-scoring
retinal endothelial samples (average RIN=9.2). The target
size profile shifts to lower molecular weight RNA frag-
ments when the low-scoring RNA was used to produce
microarray target and overall target yield was threefold
lower than that of the high-scoring total RNA samples.
Microarray expression profiles
All samples that passed core laboratory total RNA quality
assessment performed well in the microarray hybridization
assay. Typical array performance metrics are shown in
Table 2 for a variety of ocular tissues and GeneChip array
types. In general, samples displayed 3′/5′ ratios for the
GeneChip ‘housekeeping’ control genes, actin and
GAPDH, of 3 or less, indicative of minimal RNA
degradation prior to target labeling. Overall transcript
detection, as measured by the % present (%P) call
generated with the MAS 5.0 analysis algorithm, varied
with array and tissue type. In general, performance of the
ocular samples in the microarray expression assay was
similar to other high-quality mammalian RNA samples
profiled in the core. An exception to this performance
pattern is the microarray data produced from the human
retinal endothelial cell target produced from RNA with a
RIN score of 4.2. The %P for this sample was only 55%
compared to the population average of 60% for this tissue;
the actin 3′/5′ ratio was 3.43, two and a half times higher
than the typical ratio for high-quality RNA inputs.
Acinar cell samples prepared from both rat and monkey
showed good overall performance. However, there was an
increased level of variation in the detection sensitivity
Fig. 2 Bioanalyzer electrophero-
grams of microaray targets. Elec-
tropherogram traces for
approximately 200 ng of cRNA
t a r g e ta p p l i e dt oa nR N AN a n o
Chip were generated on the 2100
Bioanalyzer using the mRNA
sizing program. a Human brain
control cRNA target; b human
cornea epithelial cells; c human
choroid endothelial cells; d
human retinal endothelial cells; e
Rhesus macaque lacrimal gland
acinar cells; f Rhesus macaque
lacrimal gland
246 j ocul biol dis inform (2009) 2:243–249metric, %P, with the nine monkey lacrimal gland acinar
cell samples profiled (40–44%P) compared to typical
performance for other sets of similar samples in which
%P standard deviation is less than 1%. The GeneChip
Rhesus Genome array contains 52,000 probes sets
designed to monitor expression of 47,000 potential tran-
scripts [13]. Therefore, a difference of 4% in detection
sensitivity corresponds to a loss of detection of about 2,000
probe sets. Figure 3 shows the monkey acinar cell target
electropherograms for the samples with the lowest %P
value and the highest. The lower sensitivity values
correspond to the samples that showed the highest peaks
in the Bioanalyzer trace. The higher %P values were
associated with samples showing lower peaks and an
overall target size distribution more similar to the majority
of tissues profiled in the core.
To gain further insight on the unusual expression profiles
seen with the lacrimal gland, we determined which gene
transcripts were measured at the highest levels for each
sample. Transcripts for lipocalin 1, LCN1 (tear prealbu-
min), showed the highest hybridization signal in the
monkey lacrimal gland samples. This suggests that LCN1
mRNA may correspond to the sharp peak seen in the target
Bioanalyzer trace for lacrimal gland in Fig. 1f. Other
abundant mRNAs associated with lacrimal gland function
[14] may also contribute to the atypical peaks in the
lacrimal gland and acinar cell electropherograms. Variation
in genes represented on the rat and monkey arrays and
limited annotation for many of the probes sets tiled on the
Rhesus Genome array make it difficult at this time to
identify the full complement of gene transcripts measured at
the highest levels on the microarrays included in this study.
Table 2 Microarray expression profiling performance metrics
Tissue/cell Species Array %P 3′/5′ actin 3′/5′ GAPDH n
Retinal endothelial cells Human Human U95Av2 57.8 1.16 0.95 2
Retinal endothelial cells Human Human focus 60.0 1.71 1.54 27
Choroid endothelial cells Human Human focus 60.2 1.27 1.07 18
Retinal pigment epithelial cell line Human Human U133_Plus2 49.9 1.73 0.96 11
Cornea epithelium cell line Human Human U133_Plus2 46.7 1.98 1.03 16
Acinar cell primary culture Monkey Rhesus genome 42.2 1.8 2.5 15
Conjunctiva primary culture Monkey Rhesus genome 43.6 1.57 1.37 2
Lacrimal gland tissue Monkey Human U95Av2 29.1 5.61 2.72 2
Acinar cell primary culture Rat Rat 230_2 51.3 2.47 0.86 10
Lens epithelial cells Rat Rat U34A 50.7 1.43 0.97 4
Fig. 3 Target assessment patterns of lacrimal gland samples. Electro-
pherogrampatternsformicroarraytargetspreparedfromRhesusmacaque
lacrimal gland acinar cells. The gray dotted line corresponds to target
prepared from high-quality human brain RNA. a Electropherogram
traces of the two targets associated with the lowest %P measured in the
microarray assay for group of 9 acinar cell samples processsed together;
b electropherogram traces of the two targets associated with the highest
%P measured in the microarray assay
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Transcriptome profiling of primary tissues, cultured cells,
and immortalized cell lines is crucially dependent on the
quality of the cellular RNA used for the microarray assay.
Spectrophotometric measurements and molecular sizing
with the 2100 Bioanalyzer have proven to be extremely
useful for identifying contaminated and degraded RNA that
will underperform in the microarray assay [1, 2]. In our
core laboratory, we have successfully generated microarray
profiles from a variety of ocular tissues and cells by
following a workflow that tests total RNA and cRNA target
quality prior to array assay. Successful use of this data in
expression studies of lens epithelium [15], trabecular
meshwork [16], and human retinal and choroidal vascular
endothelium [17] have been previously described. These
studies along with reports by others on ocular tissues, such
as cornea [18], mouse and rat lacrimal gland [19, 20], and
rat and iris ciliary body [21], demonstrate the potential for
informative expression profiling of ocular tissues and cells.
Lacrimal gland and acinar cells prepared from the
lacrimal gland have an unusual target profile that is
associated with an increased variation in microarray assay
performance in some sample groups. The presence of
discrete peaks in the lacrimal gland samples is similar to
the profiles seen with whole blood RNA samples in which
high levels of hemoglobin mRNAs result in one or two
large, sharp peaks in the Bioanalyzer trace of targets
prepared from blood RNA [6, 10]. The highly abundant
hemoglobin mRNA can contribute to reduced sensitivity in
the microarray expression assay and increased sample-to-
sample variation [5–8]. It has been suggested that increased
non-specific hybridization from a few very highly
expressed mRNAs can result in decreased detection of
other less abundant gene transcripts [7]. Variation in the
levels of high-abundance mRNAs due either to physiolog-
ical differences among samples or differences in cell/tissue
collection methods would then result in differences in
overall signal distribution among samples that could
contribute to inaccurate assessments of differential expres-
sion for some genes. The results we observe with lacrimal
gland and acinar cell samples suggest that there is potential
for similar problems with this tissue. Inspection of cRNA
target traces prior to microarray assay can help determine
whether high abundance of one or a few mRNA transcripts
or a large variation in the levels of these transcripts among
samples is likely to affect the microarray hybridization.
Removal of globin transcripts prior to labeling or blocking
these transcripts during the reverse transcription step of the
labeling procedure has been shown to produce improved
microarray data from whole blood samples [6, 9, 10]. For
expression profiling studies of lacrimal gland, similar
approaches may be of value. High abundance and variable
levels of lipocalin RNA and other highly expressed genes
involved in tear production and secretion may contribute to
apparent changes in transcript levels of other genes or
inability to detect some mRNAs due to cross-hybridization
of the abundant transcripts to probes on the array. Samples
with the highest levels of a few abundant mRNAs will also
tend to have the lowest measured sensitivity in the array
assay. This may be incorrectly interpreted as a reduction in
overall transcriptome complexity.
In conclusion, our work demonstrates that multiple
ocular tissues and cell lines perform well in the microarray
expression profiling assay. Routine generation of high-
quality data requires both standardized laboratory proce-
dures and multiple quality control steps, as outlined in
Fig. 1. Our results also show that array performance
characteristics are both tissue and array specific; we provide
average metrics for a variety of ocular sample types that
may be used for benchmarking. Finally, we suggest that
conditions or sample treatments that modify lacrimal gland
secretion may lead to artifactual differences among array
expression profiles due to the presence of a few highly
abundant mRNA transcripts associated with the secretory
function of this tissue.
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